INDP

Peers: CYPH XCUR CNTN LITS KTTA TCRT CDT ELAB ONCO SCNI

Index	-
Market Cap	459.21M
Enterprise Value	447.66M
Income	-15.42M
Sales	0.00M
Book/sh	0.09
Cash/sh	0.08
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	5
IPO	Dec 26, 2012

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	35.03
P/C	39.76
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	19.48
Current Ratio	19.48
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-6.97
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	23.68% 36.34%
Sales past 3/5Y	- -
EPS Y/Y TTM	81.43%
Sales Y/Y TTM	-
EPS Q/Q	99.83%
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	- -

Insider Own	96.45%
Insider Trans	0.00%
Inst Own	0.25%
Inst Trans	257.29%
ROA	-163.84%
ROE	-318.04%
ROIC	-135.62%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	10.27%
SMA50	33.45%
SMA200	31.15%
Trades

Shs Outstand	133.24M
Shs Float	5.46M
Short Float	15.06%
Short Ratio	0.94
Short Interest	0.82M
52W High	5.96 -49.83%
52W Low	0.92 225.00%
Volatility	16.93% 16.91%
ATR (14)	0.39
RSI (14)	55.94
Beta	1.02
Rel Volume	0.70
Avg Volume	875.14K
Volume	169,807

Perf Week	35.29%
Perf Month	-25.06%
Perf Quarter	7.94%
Perf Half Y	-13.08%
Perf YTD	2.75%
Perf Year	-16.71%
Perf 3Y	-95.84%
Perf 5Y	-98.61%
Perf 10Y	-99.97%
Recom	1.00
Target Price	10.00
Prev Close	2.96
Price	2.99
Change %	1.01%

Sep-24-26 11:23PM	MRNA On Track To Be September's No. 2 S&P 500 Stock But These 5 Smaller Health Care Names Did Even Better (Stocktwits) +6.10%
Aug-13-26 07:00AM	Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-15-26 07:00AM	Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -9.14%
Dec-29-25 07:00AM	Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar (GlobeNewswire) +6.67%
Nov-17-25 08:00AM	Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit (GlobeNewswire) -9.56%
08:30AM	Loading…
Nov-12-25 08:30AM	Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +6.25%
Sep-04-25 04:01PM	Indaptus Therapeutics Provides Clinical Update (GlobeNewswire) -14.63% -28.35%
Sep-02-25 04:05PM	Indaptus Therapeutics to Present at the H.C. Wainwright 27?? Annual Global Investment Conference (GlobeNewswire) -5.34% -12.24%
Aug-13-25 08:00AM	Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-01-25 08:14AM	Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants (GlobeNewswire) +5.89%
Jun-25-25 07:00AM	Indaptus Therapeutics Announces Reverse Stock Split (GlobeNewswire) -18.29%
Jun-24-25 12:52PM	Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices (PR Newswire) -9.92%
Jun-13-25 08:00AM	Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants (GlobeNewswire)
Jun-02-25 08:00AM	Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab (GlobeNewswire)
May-14-25 08:00AM	Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Loading…
May-08-25 08:00AM	Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit (GlobeNewswire)
Mar-25-25 08:00AM	Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit (GlobeNewswire) +7.96%
Mar-20-25 08:00AM	Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20 (GlobeNewswire)
Mar-18-25 08:00AM	Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab (GlobeNewswire)
Mar-13-25 07:30AM	Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-12-25 04:15PM	Registration Is Now Open For Tribe Public's Webinar Event Keys To The Kingdom: Unlocking The Power Of Your Immune System Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025 (GlobeNewswire)
Mar-04-25 08:00AM	Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments (GlobeNewswire)
Feb-25-25 08:00AM	Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit (GlobeNewswire)
Feb-05-25 08:00AM	Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20 (GlobeNewswire) -9.49%
Jan-13-25 08:00AM	Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Jan-08-25 08:00AM	Indaptus Therapeutics Provides Year-End Review and Outlook for 2025 (GlobeNewswire)
Nov-22-24 08:36AM	Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire)
Nov-12-24 08:00AM	Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-11-24 08:00AM	Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology (GlobeNewswire)
Nov-07-24 08:00AM	Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting (GlobeNewswire)
08:00AM	Loading…
Oct-23-24 08:00AM	Indaptus Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) -11.40%
Oct-22-24 08:00AM	Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations (GlobeNewswire) +29.76%
Oct-15-24 08:00AM	Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data (GlobeNewswire)
Oct-10-24 08:00AM	Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy (GlobeNewswire)
Oct-08-24 08:00AM	Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-05-24 08:30AM	Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses (GlobeNewswire)
Sep-03-24 08:00AM	Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-12-24 08:00AM	Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-24 07:00AM	Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire)
Jun-11-24 08:00AM	Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit (GlobeNewswire)
Jun-04-24 08:00AM	Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference (GlobeNewswire)
Jun-03-24 08:00AM	Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20 (GlobeNewswire) +18.14%
May-30-24 08:00AM	Indaptus Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) -10.14%
May-29-24 08:00AM	Indaptus Therapeutics to Present New Cohort Data Confirming Original Pulse-Prime Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting (GlobeNewswire) +12.20%
May-22-24 08:00AM	Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company's Broad-Based, Pulse-Prime Immuno-Oncology Therapy for Advanced Solid Tumors (GlobeNewswire) +5.53%
May-08-24 12:54PM	INDP Stock Earnings: Indaptus Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
08:00AM	Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-11-24 07:30AM	Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting (GlobeNewswire) +9.13%
Mar-28-24 08:00AM	Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference (GlobeNewswire) -10.04%
Mar-25-24 08:30AM	Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting (GlobeNewswire) +6.90%
Mar-18-24 08:00AM	Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024 (GlobeNewswire)
Mar-13-24 07:30AM	Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-04-24 07:30AM	Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort (GlobeNewswire) +12.92%
Feb-15-24 08:00AM	Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire)
Feb-08-24 08:00AM	Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels (GlobeNewswire)
Jan-04-24 08:00AM	European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology (GlobeNewswire)
Nov-06-23 04:01PM	Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +7.20% -10.07%
08:00AM	Indaptus Therapeutics' Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study (GlobeNewswire)
Oct-31-23 09:01AM	Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting (GlobeNewswire)
Sep-27-23 08:00AM	Indaptus Therapeutics to Present at the LD Micro Main Event XVI (GlobeNewswire)
Sep-26-23 08:00AM	Registration Is Now Open For Tribe Publics Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics CEO On Friday, September 29, 2023 (GlobeNewswire) +11.65%
Sep-19-23 08:00AM	Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20 (GlobeNewswire) +7.34%
Sep-06-23 08:05AM	Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-14-23 08:00AM	Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +7.83%
Aug-10-23 08:45AM	Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20 (GlobeNewswire) +22.78%
Aug-07-23 08:00AM	Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer (GlobeNewswire)
Jun-15-23 08:00AM	Indaptus Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference (GlobeNewswire)
May-31-23 08:30AM	Indaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023 (GlobeNewswire)
May-11-23 07:00AM	Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -9.30%
May-09-23 08:00AM	Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform (GlobeNewswire) -16.18%
May-01-23 08:00AM	Indaptus Therapeutics Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit (GlobeNewswire)
Apr-24-23 09:00AM	Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV (ACCESSWIRE) -8.74%
Apr-20-23 04:05PM	Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023 (GlobeNewswire) -7.83%
Apr-19-23 09:28AM	UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023 (GlobeNewswire) +23.17%
08:05AM	Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023 (GlobeNewswire)
Apr-17-23 08:00AM	Indaptus Therapeutics Receives Brazilian Patent Allowance for Decoy Platform (GlobeNewswire)
Mar-22-23 08:00AM	Indaptus Therapeutics to Present at the Investor Summit Conference (GlobeNewswire)
Mar-17-23 08:00AM	Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +6.34%
Mar-15-23 08:05AM	Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023 (GlobeNewswire)
Mar-13-23 08:05AM	Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors (GlobeNewswire)
Mar-07-23 08:05AM	Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors (GlobeNewswire)
Feb-14-23 08:00AM	Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors (GlobeNewswire)
Feb-07-23 08:05AM	Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors (GlobeNewswire)
Dec-13-22 07:30AM	Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors (GlobeNewswire) +9.52%
Nov-10-22 04:05PM	Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +16.18%
Oct-18-22 07:00AM	Indaptus Therapeutics to Present at the LD Micro Main Event XV (GlobeNewswire)
Sep-06-22 09:02AM	Indaptus Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-08-22 08:00AM	Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-09-22 07:00AM	Indaptus Therapeutics to Present at JMP Securities Life Sciences Conference (GlobeNewswire)
Jun-03-22 07:00AM	Indaptus Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-23-22 08:00AM	Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman (GlobeNewswire)
May-19-22 07:00AM	Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors (GlobeNewswire) +18.80%
May-18-22 04:15PM	Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-12-22 08:00AM	Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-03-22 12:20PM	Indaptus Therapeutics, Inc. (NASDAQ:INDP) insiders placed bullish bets worth US$2.4m in the last 12 months (Simply Wall St.)
Apr-20-22 07:00AM	Indaptus Therapeutics to Present at 2nd Annual Chronic HBV Drug Development Summit (GlobeNewswire)
Mar-23-22 07:00AM	Indaptus Therapeutics to Present at Maxim Group 2022 Virtual Growth Conference (GlobeNewswire)
Mar-21-22 07:00AM	Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-17-22 07:00AM	Indaptus Therapeutics to Present at 3rd Annual STING & TLR-Targeting Therapies Summit (GlobeNewswire) +6.73%
Mar-07-22 07:00AM	Indaptus Therapeutics to Present at 34th Annual ROTH Conference (GlobeNewswire) -7.67%

Show Previous News

Indaptus Therapeutics, Inc. is a clinical biotechnology company. The firm engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.

CEO & ChairmanMr. Junyi Dai

Chief Financial OfficerMr. Yu Ding

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Indaptus Therapeutics Inc

Upgrade your Finviz experience